U.S. markets close in 5 hours 26 minutes

Gilead Sciences, Inc. (GILD)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
75.43+0.01 (+0.01%)
As of 10:34AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Short-term KST

Short-term KST

Previous Close75.42
Bid75.58 x 900
Ask75.58 x 800
Day's Range75.21 - 75.68
52 Week Range61.45 - 89.74
Avg. Volume5,471,366
Market Cap93.987B
Beta (5Y Monthly)0.39
PE Ratio (TTM)17.34
EPS (TTM)4.35
Earnings DateOct 25, 2023 - Oct 30, 2023
Forward Dividend & Yield3.00 (3.98%)
Ex-Dividend DateSep 14, 2023
1y Target Est91.04
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
41% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for GILD

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Gilead Sciences, Inc.
    Analyst Report: Gilead Sciences, Inc.Gilead Sciences is a biopharmaceutical company that researches, develops, and sells therapies for treating HIV, hepatitis B, hepatitis C, and certain cancers. In October 2020, Gilead's Veklury (remdesivir) became the first approved treatment for COVID-19 in the U.S. Founded in 1987, the company is located in Foster City, California. It has operations in more than 35 countries and approximately 17,000 employees.
    Fair Value
    Economic Moat
    11 days agoArgus Research
View more